Back

Loss of adipocyte phospholipase gene PLAAT3 causes lipodystrophy and insulin resistance due to inactivated arachidonic acid-mediated PPAR signaling

Schuermans, N.; El Chehadeh, S.; Hemelsoet, D.; Bogaert, E.; Debackere, E.; Hilbert, P.; Van Doninck, N.; Taquet, M.-C.; Rosseel, T.; De Clercq, G.; Van Haverbeke, C.; Chanson, J.-B.; Funalot, B.; Authier, F.-J.; Kaya, S.; Terryn, W.; Callens, S.; Depypere, B.; Van Dorpe, J.; Program for Undiagnosed Diseases (UD-PrOZA), ; Poppe, B.; Depienne, C.; Dermaut, B.

2021-04-15 genetics
10.1101/2021.04.15.439941 bioRxiv
Show abstract

PLAAT3 is a phospholipid modifying enzyme predominantly expressed in white adipose tissue (WAT). It is a candidate drug target as Plaat3 deficiency in mice protects against picornavirus infection and diet-induced obesity. We identified four patients with homozygous loss-of-function mutations in PLAAT3, presenting with partial lipodystrophy, severe insulin resistance and dyslipidemia. PLAAT3-deficient WAT showed a failure to liberate arachidonic acid (AA) from membrane phospholipids resulting in an inactive gene network downstream of adipogenesis master regulator and anti-diabetic drug target PPARG. These findings establish PLAAT3 deficiency in humans as a novel type of partial lipodystrophy due to an AA- and PPARG-dependent defect in WAT differentiation and function.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.